Latest News for: 3750

Edit

Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3-6

PR Newswire 07 Apr 2025
Results highlight safety and promising clinical responses of R-3750, along with biomarker results demonstrating a differentiated immune mechanism ... R-3750, a novel oral immunotherapy, is ...
  • 1
×